Siglec-8 as mast cell selective target: developing paradigms amidst inconvenient truths

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Systemic mast cell activation disease (MCAS) treatments have limited efficacy, driving the need for novel, mast cell-selective therapies.
• Past drug development has relied on cell culture and leukocyte studies, often failing verification in organ and animal models.
• The purported selective expression of sialic acid binding Ig-like lectin 8 (Siglec-8) on mast cells is a recent example of challenged paradigms.

Purpose of the Study:

• To critically evaluate the claimed mast cell selectivity of Siglec-8 as a therapeutic target.
• To highlight the widespread expression of Siglec-8 beyond mast cells and eosinophils.
• To provide recommendations for developing targeted therapies and interpreting scientific literature.

Main Methods:

• Analysis of publicly available gene expression databases and sources.
• Review of existing literature on Siglec-8 expression and mast cell-targeting strategies.
• Critical assessment of scientific claims regarding target selectivity.

Main Results:

• Data indicate Siglec-8 is expressed widely across various tissues and cell types, not selectively in mast cells and eosinophils.
• The assumption of Siglec-8 mast cell selectivity is not supported by current evidence.
• Potential for severe adverse effects exists if Siglec-8-based therapies target its widespread expression.

Conclusions:

• Therapeutic strategies targeting Siglec-8 must consider its limited mast cell selectivity and potential off-target effects.
• Researchers and clinicians should critically evaluate claims of selective target expression, even in high-impact publications.
• Further investigation is needed to identify truly mast cell-selective targets for effective MCAS treatment.